For many years, Becton Dickinson (NYSE:BDX) has been summarily dismissed by a lot of portfolio managers as "too boring". Well, their loss. Although the stock of this diversified health care and biosciences company could not match the pace of health care all-star Medtronic (NYSE:MDT), it stacks up quite well against the likes of Abbott Labs (NYSE:ABT), Baxter (NYSE:BAX) and many other more "exciting" names. Proof, perhaps, that the steak is more satisfying than the sizzle.

IN PICTURES: 20 Tools For Building Up Your Portfolio

A Quiet Quarter
The first quarter of 2010 was pretty much medium, with little to get excited about in either direction. Revenue growth of about 7% was in line with expectations, while the earnings per share (ex-items) were four cents ahead of the average estimate.

Results across the company's three major business lines were mixed. Strong results in diabetes care and pharmaceutical systems helped offset weakness in medical surgical systems (largely injection, infusion and infection-prevention products) in the BD Medical segment. Diagnostics saw results in cancer and STD testing offset a decline in flu testing, while cell analysis products helped boost results in the biosciences business. (For related reading, check out A Checklist For Successful Medical Technology Investment.)

New Tech Can Maintain the Momentum
It seems practically a given that Becton Dickinson will increasingly tie the future of its growth to advanced diagnostics and bio-research products. In diagnostics, the company faces stiff competition from companies like Roche (Nasdaq:RHHBY), Qiagen (Nasdaq:QGEN) and Gen-Probe (Nasdaq:GPRO) in its STD testing franchise, and Cepheid (Nasdaq:CPHD) in hospital-acquired infections.

To compete, the company plans to roll out a new molecular diagnostics platform, the BD MAX, in 2011. This automated real-time PCR platform could go a long way in tapping the fast-growing molecular diagnostics market. Of course, Cephied and Gen-Probe have their own automated systems (with Gen-Probe's new Panther expected in the U.S. in 2011), so the battle should really get interesting at that point.

Likewise, expect the company to continue to look to innovate or acquire to build up the biosciences business. With BDX's existing strength in flow cytometry, it wouldn't be surprising to see them interested in a fast-growing company like Luminex (Nasdaq:LMNX). But even if the company foregoes acquisitions (or at least acquisitions of that size), expect management to preferentially invest in a market segment whose growth should outpace that of BDX's other markets by a reasonable margin.

A Stock That Gives You Second Chances
Becton Dickinson isn't all that expensive at today's prices. That said, this is a stock that always seems to give investors a pullback of at least 10% every year. Perhaps we already saw that move when the stock went from about $80.50 around the end of last year to below to below $75 in early February, or maybe there is a second slide to come. In either case, you don't have to rush to buy this stock. It is a fine company as is, but if you can get it for 10% less, why not wait it out?

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Alternative Energy Stocks for 2016 (AMSC, SLTD)

    Follow a cautious approach when purchasing micro-cap stocks in the alternative energy sector. Learn about five alternative energy micro-caps worth considering.
  7. Stock Analysis

    Analyzing Porter's Five Forces on Under Armour (UA)

    Learn about Under Armour and how it differentiates itself in the competitive athletic apparel industry in light of the Porter's Five Forces Model.
  8. Stock Analysis

    The Biggest Risks of Investing in Qualcomm Stock (QCOM, BRCM)

    Understand the long-term fundamental risks related to investing in Qualcomm stock, and how financial ratios also play into the investment consideration.
  9. Stock Analysis

    The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ)

    Learn the largest risks to investing in Johnson & Johnson through fundamental analysis and other potential risks. Also discover how JNJ compares to its peers.
  10. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  1. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  2. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  3. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  4. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  5. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
  6. What is the formula for calculating earnings per share (EPS)?

    Earnings per share (EPS) is the portion of a company’s profit that is allocated to each outstanding share of common stock, ... Read Full Answer >>
Trading Center